A5021860279- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Gastric Cancer Management and Outcomes
- Gestational Trophoblastic Disease Studies
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Brain Metastases and Treatment
- Breast Lesions and Carcinomas
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- MicroRNA in disease regulation
- Thyroid Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- Cancer Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Ovarian cancer diagnosis and treatment
Istituto Superiore di Sanità
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
Federico II University Hospital
2024
Research Institute Hospital 12 de Octubre
2019-2023
Hospital Universitario 12 De Octubre
2018-2023
Fondazione Santa Lucia
2023
Ospedale San Luigi Gonzaga
2016-2022
University of Turin
2016-2020
Centro de Investigación Biomédica en Red de Cáncer
2019-2020
Fondazione IRCCS Istituto Nazionale dei Tumori
2018
BackgroundSolid tumour growth is the consequence of a complex interplay between cancer cells and their microenvironment. Recently, new global transcriptomic immune classification solid tumours has identified six subtypes (ISs) (C1–C6). Our aim was to specifically characterise ISs in colorectal (CRC) assess with consensus molecular (CMSs).MethodsClinical information, including CMSs ISs, were obtained from The Cancer Genome Atlas (TCGA) (N = 625). Immune cell populations, differential gene...
Abstract Background Lung neuroendocrine neoplasms (NENs) represent about 20% of all lung cancers. Few therapeutic options are available for atypical carcinoids (ACs). Single-agent temozolomide (TEM) is active in NENs, but whether the addition capecitabine (CAPTEM) associated with improved outcomes, unknown. We sought to investigate TEM-based therapies (TEM or CAPTEM) patients advanced AC. Material and methods This was a retrospective analysis prospectively collected data from AC referred our...
Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) radiological disease progression according to Response Evaluation Criteria Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion...
Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data both combined lacking. ATLANT (NCT02698410) evaluated efficacy safety of LAN/TMZ in progressive T-NETs. Methods: was a 12-month, Italian, phase 2, single-arm, open-label, multicenter pilot study. Eligible patients had unresectable, locally advanced/metastatic, well-/moderately differentiated T-NETs with...
Well-differentiated lung neuroendocrine tumors (Lu-NET) are classified as typical (TC) and atypical (AC) carcinoids, based on mitotic counts necrosis. However, prognostic factors, other than tumor node metastasis (TNM) stage the histopathological diagnosis, still lacking. The current study is aimed to identify potential factors better stratify NET, thus, improving patients' treatment strategy follow-up.A multicentric retrospective study, including 300 Lung all surgically removed, from...